drugset / Trial / NCT02845843

MERS-CoV Infection tReated With A Combination of Lopinavir /Ritonavir and Interferon Beta-1b

NCT02845843

Phase 2/3 Completed 95 enrolled King Abdullah International Medical Research Center
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a placebo-controlled clinical trial to assess the efficacy and safety of a combination of lopinavir/ritonavir and Interferon beta-1b in hospitalized patients with MERS.

Timeline

Start
2016-07
Primary completion
2020-05
Completion
2020-05

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Interferon beta-1b Protein / enzyme biologic 0.25 mg Subcutaneous
Subject Lopinavir Other / unclassified 400 mg
Subject Ritonavir Other / unclassified 100 mg